Jon Weidanz via UTA
UTA cancer expert explores making personalized treatments effective for multiple patients
In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective “off-the-shelf” cancer treatments for more patients.
Jon Weidanz, who also is a professor in the College of Nursing and Health Innovation at UTA, is the author of a perspective regarding the development of cancer immunotherapies.
His article, “Targeting cancer with bispecific antibodies,” will appear in the March 5 edition of Science. It evaluates the findings of three studies by researchers at Johns Hopkins University and proposes that an emerging method of protein-based immunotherapy that targets commonly occurring mutations in cancer cells or neoantigens—mutated antigens produced by tumor cells—could lead to treatments that are effective for oncology patients.
Immunotherapy, a method to treat illness by stimulating a person’s immune system, is a developing alternative to traditional cancer treatments.
“Up until recently patients were limited to four treatment options: surgery, radiation, chemotherapy and targeted therapy,” Weidanz said. “However, the holy grail has always been to develop strategies that would harness the power of the immune system to attack and destroy the cancer. With recent breakthroughs in immuno-oncology along with the new findings being published in Science, it does appear we are closing in on cancer with new immunotherapies.”
As medicine has advanced, immunologists have discovered ways to engineer a person’s T-cells, the white blood cells that fight and kill infected cells, to recognize and target cancer cells and eliminate them from the body. This approach has led to exciting advances in the field and remission in some patients. However, more work is required to make this form of T-cell therapy more broadly accessible.
Alternatively, researchers have developed approaches that stimulate the immune system without removing T-cells from the body. These “off-the-shelf” protein-based treatments, known as bispecific T-cell engaging antibodies, have proven effective in treating patients with acute lymphoblastic leukemia, a type of blood cancer.
“The ideal is to create protein molecules that have two arms. One arm can recognize the cancer cell and bind to it. The other arm binds to T-cells,” Weidanz said. “The protein drug then brings the T-cells into proximity with the tumor cells, which activate the T-cells to destroy the tumor cells.”
These two-armed, or bispecific, proteins would avoid healthy cells while destroying cancer cells. Weidanz argues that this method of protein-based immunotherapy could make a difference. The key comes down to the unique targets expressed by the cancer cells that the bispecific protein drug recognizes. Bispecific antibodies could bind to particular neoantigen targets found on tumor cells and recruit T-cells to destroy the cancer.
“The beauty of bispecific proteins is that you could manufacture those proteins and put them on the shelf as an immunotherapy agent,” Weidanz said. “If a doctor sees that a patient’s cancer expresses the neoantigen target, they could be treated immediately. It’s still a personalized medicine, but would not require engineering T-cells.”
An expert in immunology, Weidanz has more than 30 years of experience in biotechnology research with an emphasis on immunotherapy, especially related to oncology and product development to diagnose and treat cancer. His research lab at UTA investigates how the immune system identifies malignant cells with the goal of designing treatments that boost immune cells’ ability to destroy cancerous cells.
“Dr. Weidanz’s substantial expertise in the field of immunology will lead us into the next generation of cancer management,” said James Grover, interim vice president of research. “The developments of his lab and those of his many talented colleagues across the nation make this a pivotal moment in the history of a devastating disease.”
Weidanz said immunotherapy holds the promise of transforming cancer into a more manageable condition with better prognoses for patients.
“We are getting to a point where we will be able to make cancer more of a chronic disease,” Weidanz said. “Now, we look at five-year survival. Maybe we can start looking at 15- or 20-year survival readouts because we’re able to manage the disease with immunotherapies that are being developed. It’s a very exciting time.”
Original Article: Future of immunotherapy could be “off-the-shelf treatments
More from: University of Texas at Arlington | Johns Hopkins University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- 13 Plant-Based Recipes That Pump Up The Protein
If you follow a plant-based or vegan eating plan, how you get enough protein is typically the first thing people ask about. But plant-based protein... Photo Credit: The Gracious Pantry. This Chickpea ...
- Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases, announces the award of a grant from CQDM, a Canadian ...
- Best Protein Powder Of 2023, According To Experts
Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board. Getting enough daily protein is important for your overall health, and if you’re having a ...
- 20 Best Plant Based Protein Powders in 2023
We may receive a commission for purchases made through these links. Are you looking for the best plant-based protein powders on the market? If so, you've come to the right place. In this blog post, we ...
- 18 Best Low Carb Protein Powders in 2023
Second, consider the type of protein powder. There are whey, casein, and plant-based options. Whey protein is a fast-digesting protein that's great for post-workout recovery. Casein protein is a ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”protein-based immunotherapies ” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- Brenus Pharma announces its international Scientific Committee
This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid ...
- Untapping the full potential of immunotherapies for more people with cancer
Immunotherapy works by sparking the body’s own immune system into action against tumours. It has become a first-choice treatment for some types of cancer, and now there are exciting opportunities to ...
- Novocure's lung cancer device study raises concerns around commercial use
Novocure said on Tuesday its experimental device to treat a type of lung cancer showed a statistically significant improvement in extending overall survival among patients in a late-stage study.
- Head and neck cancer data presented at ASCO 2023
Results from two trials in the fight against head and neck cancer have been presented at the ASCO annual meeting in Chicago.
- Cellular Immunotherapy to Target NY-ESO-1 for Metastatic Melanoma by Avalia Immunotherapies for Metastatic Melanoma: Likelihood of Approval
Cellular Immunotherapy to Target NY-ESO-1 for Metastatic Melanomais under clinical development by Avalia Immunotherapies and currently in Phase II for Metastatic Melanoma.
Go deeper with Google Headlines on:
[google_news title=”” keyword=”immunotherapies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]